Acumen Pharmaceuticals extends collaboration with Lonza for sabirnetug
Sabirnetug is a humanised monoclonal antibody that has shown selective target engagement with toxic soluble amyloid beta (Aβ) oligomers in patients with AD. The partnership between Acumen and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.